Pay in 4 interest-free payments of $5.86 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Qsymia (phentermine-topiramate) is not licensed for use in the UK by the MHRA Wegovy (semaglutide) is a GLP-1 receptor agonist licensed in the UK and should not be combined with other weight management products according to its Summary of Product Characteristics No clinical trials have investigated the safety or efficacy of combining these two medications Potential risks include cardiovascular effects, amplified gastrointestinal side effects, and central nervous system disturbances UK guidance from NICE recommends single-agent pharmacotherapy optimised within specialist weight management services Sequential therapy or bariatric surgery referral are evidence-based alternatives for patients not responding to single-agent treatment Table of Contents Understanding Qsymia and Wegovy: Different Mechanisms for Weight Loss Can You Take Qsymia and Wegovy Together
PMID: 38952487 13 Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials
You may be able to shed some initial weight, but after a while you will reach a plateau and your semaglutide will no longer be working as it did for you before
However, gathering all these supplies and ensuring they meet research-grade standards can be frustrating
Consistent, adequate protein signals to your body that lean tissue is needed and should be maintained while fat stores are the preferred energy source
